Urolithin A Reduces Anxiety by Restoring Brain Mitochondrial Function
Gut metabolite urolithin A dramatically reduced anxiety in rodent models by fixing mitochondrial dysfunction in brain reward circuits.
Summary
Researchers discovered that urolithin A, a compound produced by gut bacteria from pomegranates and berries, powerfully reduces anxiety by restoring mitochondrial health in brain cells. In two different rodent models of high anxiety, chronic urolithin A treatment eliminated anxious behaviors without affecting normal animals. The compound worked by normalizing mitochondrial gene expression and repairing synaptic connections in the nucleus accumbens, a key brain reward region. This represents the first evidence that urolithin A can treat anxiety disorders through mitochondrial mechanisms.
Detailed Summary
Chronic anxiety affects millions but current treatments often fail, prompting researchers to explore novel therapeutic targets. Scientists at École Polytechnique Fédérale de Lausanne investigated whether urolithin A, a gut bacteria metabolite known for enhancing mitochondrial function, could alleviate anxiety disorders.
The team tested urolithin A in two validated rodent anxiety models: naturally anxious animals and rats bred for high stress reactivity. They used comprehensive behavioral testing, single-cell brain analysis, and electrophysiology to understand the mechanisms.
Urolithin A produced remarkable anxiolytic effects in both high-anxiety models across both sexes, while leaving low-anxiety animals unaffected. Brain analysis revealed that anxious animals had disrupted mitochondrial and synaptic gene networks in nucleus accumbens neurons. Urolithin A normalized these molecular signatures to match low-anxiety levels, restored dendritic spine density, and improved synaptic transmission. Notably, the compound restored Mfn2, a mitochondrial protein previously linked to anxiety regulation.
These findings suggest urolithin A could offer a mechanistically novel approach to treating anxiety disorders by targeting mitochondrial dysfunction. The compound's selective effects on high-anxiety individuals, combined with its established safety profile, make it particularly promising for clinical translation. However, human studies are needed to confirm these preclinical results and establish optimal dosing protocols.
Key Findings
- Urolithin A eliminated anxiety behaviors in two rodent models without affecting normal animals
- Treatment restored mitochondrial gene expression in brain reward circuits
- Compound repaired synaptic connections and dendritic spine density
- Effects were consistent across both male and female subjects
- Urolithin A normalized Mfn2 protein linked to anxiety regulation
Methodology
Researchers used two validated rodent anxiety models with chronic urolithin A treatment, employing single-nucleus RNA sequencing of brain tissue, behavioral testing across multiple anxiety tasks, and electrophysiological measurements of synaptic function.
Study Limitations
This summary is based on the abstract only, limiting detailed analysis. Human studies are needed to confirm these preclinical findings and establish clinical efficacy and dosing protocols.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.